Global Orphan Drug Access and Pricing in Emerging Markets Report 2018: Budget Limitations are a Major Hurdle but Opportunities Still Exist for Some Rare Diseases - ResearchAndMarkets.com

DUBLIN--()--The "Orphan Drug Access and Pricing in Emerging Markets" report has been added to ResearchAndMarkets.com's offering.

This analysis covers the four major emerging regions of the Middle East and Africa, Latin America, Eastern Europe, and Asia-Pacific. Within these regions, relatively wealthier markets with a proven marketplace for orphan medicines have been prioritized.

The topic focus is on rare-disease policy, access, and pricing, as well as the stakeholder landscape for low-prevalence disorders and orphan drugs.

For the purposes of this analysis, local definitions for rare disease were used where available, as well as conventional definitions of both ultra-orphan disorders and rare tumor types.

The insights in this analysis are aimed at a general audience within the market access and pricing field, with a limited amount of disease-specific information. In this review, key market access customers for rare diseases in 20 emerging markets have been analyzed, as well as pricing and funding pathways where these specifically relate to orphan drugs.

Key Topics Covered:

EXECUTIVE SUMMARY

Budget limitations are a major hurdle but opportunities still exist for some rare diseases

Each market will require customized access strategy to maximize chance of success

Lack of diagnosis and treatment infrastructure, coupled with payer rigidity present key access challenges

Gulf region presents the most lucrative opportunity, with well-funded niches in other regions

KEY FEATURES OF EMERGING ORPHAN DRUG MARKETS

Orphan drugs and emerging markets are industry growth engines

The orphan drug business model requires local adaptation

Bibliography

RARE DISEASE POLICY AND CAPABILITY

Prevalence-based definitions of rare diseases are a critical step

Legal frameworks are often incoherent

Challenges in diagnostic and treatment infrastructure

Policy does not guarantee access

Bibliography

PRICING, REIMBURSEMENT, AND MARKET ACCESS

Payers' rigidity is the key market access challenge

Exceptional access mechanisms exist in some leading emerging markets

Payers misuse international price referencing for orphan drugs

Registries are evolving in emerging markets

Bibliography

PRIORITY EMERGING ORPHAN DRUG MARKETS

The Gulf states are the stand-out opportunity

Only the Middle East matches prevalence with funding

Heterogeneity drives specific local needs

Emerging markets are not ready for new technology

Manufacturers should match resources to access

Bibliography

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/kvvhtz/global_orphan?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Pharmacoeconomics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Pharmacoeconomics